Drug Topics Newsletter

To view this email as a web page, click here.

PHARMACISTS' REPORT

Opinion: Big Storm Brewing for American Specialty Pharmacies and Patients

Specialty pharmacy prescriptions are plagued by a myraid of complications.

AbbVie’s Skyrizi Granted Regulatory Approval

Risankizumab-rzaa has been approved for adults with moderate to severe plaque psoriasis.

The state of Biosimiars in 2019

While still largely a new phenomenon, biosimilars are here to stay—and this year will only bring more of them to market.

Side Effects of the Shingles Vaccines

What patients can expect after Shingrix or Zostavax injections.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.